A novel Peptide drug for the treatment of wet-AMD

Anti-VEGF therapy is the current standard treatment for wet-AMD and consists of injections of Lucentis, Avastin or Eylea. Nearly all patients (95%) treated with anti-VEGF therapy maintained their vision, and vision improved by at least three lines (or 15 letters) in up to 40% of these patients at one year. However, evolution of sub-retinal fibrosis, which leads to irreversible visual loss was common (32% at one year and 45% at two years) in patients with wet-AMD treated with monotherapy anti-VEGF therapy.

Our synthetic small peptide antagonist DSG2 drugs provided a new mechanism for inhibiting angiogenesis with not only superior anti-angiogenic efficacy in comparison to Eylea, but also offers a new treatment mechanism against fibrosis.

DSG2 peptide drugs can be easily produced at competitive costs and could be formulated as eye drops to resolve the inconveniences caused by the current treatment of AMD by intravitreal (IVT) injection.

ASP5006 peptide drug

VEGF and non-VEGF pathways

Promising result from animal studies

In discussion with pharma for co-development